Skip to main content
SpringerLink
Log in

All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The Radiation Therapy Oncology Group enrolled 30 patientswith recurrent malignant astrocytomas onto a phase IIstudy (RTOG 91-13). Patients were treated with all-trans-retinoicacid at a starting dose of 120 mg/m2per day orally continuously until disease progression. Fourteenpatients had glioblastoma, 14 had anaplastic astrocytoma, and2 had other histologies; 53% were under 50years of age. All patients had failed radiationtherapy and/or at least one chemotherapy regimen. Allpatients had a Karnofsky performance status score ofat least 70, but only 37% had aKPS of 90-100. Forty percent had a neurologicfunction status of grade 1 (able to work).A minimum of 4 weeks of all-trans-retinoic aciddefined adequate treatment. Twenty-five patients received adequate therapy.Most common toxicities were dry skin, cheilitis, anemia,and headache; 3 patients had grade 3 headacherequiring suspension of all-trans-retinoic acid. No grade 3hematologic toxicity was observed. Of 25 adequately treatedpatients, 3 showed objective regression of tumor onmagnetic resonance imaging and computed tomography scans, 3patients remained stable, and 19 patients had diseaseprogression. The median time to tumor progression was3.8 months and the median survival time was5.7 months.This study suggests that this dose of singleagent all-trans-retinoic acid has modest clinical activity againstrecurrent malignant gliomas with tolerable side effects. Aresponse rate of 12% and a stabilization rateof 12% are lower than expected. Future studieswith higher dosage or in combination with biologicalresponse modifiers or chemotherapy may be warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Walker MD, Alexander G Jr, Hunt WE, Leventhal CM, Mahaley MS Jr, Mealey J, Norrell HA: Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44: 655–667, 1976

    Google Scholar 

  2. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahalley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49; 333–343, 1978

    Google Scholar 

  3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiotherapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1993

    Google Scholar 

  4. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep 17: 493–515, 1987

    Google Scholar 

  5. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL Jr: Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 123: 201–204, 1987

    Google Scholar 

  6. Lippman SM, Meyskens FL: Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmac Ther 40: 107–122, 1989

    Google Scholar 

  7. Lippman SM, Meyskens FL: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 107: 499–501, 1987

    Google Scholar 

  8. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315: 1501–1505, 1986

    Google Scholar 

  9. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318: 1633–1637, 1988

    Google Scholar 

  10. Lippman SM, Kessler JF, Al-Sarraf M, Alberts DS, Itri LM, Mattox D, Van Hoff DO: Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: A phase II randomized trial. Invest New Drugs 6: 51–56, 1988

    Google Scholar 

  11. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567–572, 1988

    Google Scholar 

  12. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, Daniel MT, Berger R, Castaigne S, Degos L: Retinoic acid therapy for promyelocytic leukemia. Lancet 746–747, 1989

  13. Castaigne S, Chomienne C, Ballerini P, Huang ME, Daniel MT, Berger R, Miclea JM, Degos L: All-trans-retinoic acid: A novel differentiation therapy for acute promyelocytic leukemia (Abstract) Blood 117a, 1989

  14. Yung WK, Lotan R, Lee P, Lotan D, Steck P: Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Research 49: 1014–1019, 1989

    Google Scholar 

  15. Olson JA; Adverse effects of large doses of vitamin A and retinoids. Semin Oncol 10: 290–293, 1983

    Google Scholar 

  16. Levin VA, Wilson DB, Crafts D, Norman D, Hoffer P, Spire JP: Criteria for evaluating malignant brain tumor patients undergoing chemotherapy. J Neurosurg 47: 329–335, 1977

    Google Scholar 

  17. Norman D, Enzmann D, Levin VA, Wilson CB, Newton TH: Computerized tomographic scanning in the evaluation of malignant gliomas under therapy. Radiol 121: 85–88, 1976

    Google Scholar 

  18. Caplan RJ, Pajak TF, Cox JD: Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Phys 29: 1183–1186, 1994

    Google Scholar 

  19. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Mannond GD, Fenton RM, Cannaghan GD, Hittleman WN, Poplack DG: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10: 1666–1673, 1992

    Google Scholar 

  20. Lee JS, Newman RA, Lippman SM, Huber MH, Minor J, Raber MN, Krakoff IH, Hong WK: Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11: 959–966, 1993

    Google Scholar 

  21. Kahn MJ, Luginbuhl W, Gaines L, Bratschi J, Bavaria J, Kaiser L, Treat J: Leukocytosis associated with all-trans-retinoic acid therapy in metastatic non-small cell lung cancer. J Natl Cancer Inst 84: 1669–1671, 1992

    Google Scholar 

  22. Frankel SR, Eardley A, Lauwers G: The ‘retinoic acid syndrome’ in acute promyelocytic leukemia. Ann Intern Med 117: 292–296, 1992

    Google Scholar 

  23. Koike T, Tatewaki WH, Aoki A, Yoshimoto H, Yagaisawa K, Hashimoto S, Furukawa T, Sastoh H, Takahashi M, Li-bo Y, Ying W, Shibata A: Brief report: Severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 327: 385–387, 1992

    Google Scholar 

  24. Koch HF: Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acid. J Maxillofac Surg 6: 59–63, 1978

    Google Scholar 

  25. Band PR, Besner JG, Leclaire R, Girad C, Biorio G, Deshamps M, Gelinas M, Larochelle D: Phase I study on 13-cisretinoic acid toxicity. Cancer Treat Rep 66: 1759–1761, 1982

    Google Scholar 

  26. Yung WK, Simaga M, Levin VA: 13-cis-retinoic acid: A new and potentially effective agent for recurrent malignant astrocytomas. (Abstract) Proc Am Assoc Cancer Res 12: A497, 1993

    Google Scholar 

  27. Atiba J, Jamil S, Meyskens FL Jr, Cho J, Armentrout S, Berkson P, Wong S-F, Neal J: Transretinoic acid (tRA) in the treatment of malignant gliomas (MG): A phase II study (Abstract) Proc Am Soc Clin Oncol 13: A501, 1994

    Google Scholar 

  28. Westarp ME, Westarp MP, Bollag W: Effect of six retinoids and retinoic acid catabolic inhibitor liarozole on two glioblastoma cell lines, and first experience in malignant brain tumor patients. (Abstract) Fourth International Congress on Anti-cancer Chemotherapy, February 2–5, 1993, Paris, France, 116

  29. Hoffman W, Rodemann HP, Schiller U: Retinoid and Interferon–an Induced Modulation of Proliferation and Differentiation in Human Tumor Cell Lines. (Abstract) Second International Cancer Chemo Prevention Conference, April 28–30, 1993, Berlin, Germany, 99

  30. Kalin JR, Wells MJ, Hill DL: Effects of phenobarbital, 3-methylcholanthrene, and retinoid pretreatment on disposition of orally administered retinoids in mice. Drug Metab Dispos 12: 63–67, 1984

    Google Scholar 

  31. Siegenthaler G, Saurate JH: Plasma and skin carriers for natural and synthetic retinoids. Arch Dermatol 123: 1690a–1692a, 1987

    Google Scholar 

  32. Hirschel Scholz S, Siegenthaler G, Saurat JH: Ligand-specific and non-specific in vivomodulation of human epidermal cellular retinoid acid binding protein (CRABP). Eur J Clin Invest 19: 220–227, 1989

    Google Scholar 

  33. Hirschel Scholz S, Siegenthaler G, Saurat JH: Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoid acid binding protein (CRABP). Br J Dermatol 120: 639–644, 1989

    Google Scholar 

  34. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Hatthay KK, Ramsay NKC, Reynolds CP: Phase I trial of 13 cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13: 894–900, 1995

    Google Scholar 

  35. Reynolds CP, Schlinder P, Jones D, Gentile J, Proffitt R, Einhorn P: Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. In: Evans A, Biedler JL, Brodeur G et al. (eds) Advances in Neuroblastoma Research 4. New York, NY, Wiley, 1994; 237–244

    Google Scholar 

  36. Muindi J, Frankel SR, Miller W Jr, Jukubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid ‘resistance’ in patients with acute promyelocytic leukemia. Blood 79: 299–303, 1992

    Google Scholar 

  37. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839–864, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Therapy Oncology Group, USA

    Surasak Phuphanich, Charles Scott, A. Jennifer Fischbach, Corey Langer & W.K. Alfred Yung

  2. The Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA

    Surasak Phuphanich

  3. RTOG Statistics Department, USA

    Charles Scott

  4. LDS Hospital, USA

    A. Jennifer Fischbach

  5. USA

    Corey Langer

  6. USA

    W.K. Alfred Yung

Authors
  1. Surasak Phuphanich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Jennifer Fischbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Corey Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W.K. Alfred Yung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phuphanich, S., Scott, C., Fischbach, A.J. et al. All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol 34, 193–200 (1997). https://doi.org/10.1023/A:1005765915288

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005765915288

Search

Navigation